NCT02370329View on ClinicalTrials.gov

P1101 in Treating Patients with Myelofibrosis

PHASE2CompletedINTERVENTIONAL

Enrollment

11

Participants

Timeline

Start Date

August 12, 2015

Primary Completion Date

November 30, 2023

Study Completion Date

November 30, 2023

Conditions

Primary MyelofibrosisSecondary Myelofibrosis

Interventions

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Quality-of-Life Assessment

Ancillary studies

BIOLOGICAL

Ropeginterferon Alfa-2B

Given SC

Trial Locations (1)

85259

Mayo Clinic in Arizona, Scottsdale

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Mayo Clinic

OTHER